I totally get your frustration, and it’s a valid point! The licensing and regulatory side of CBD is definitely a complex issue. Big pharmaceutical companies are less likely to invest in clinical trials for CBD because it’s a naturally occurring compound and can’t be patented in the same way synthetic drugs can. Without exclusivity, there’s less financial incentive for them to pour money into research.
What’s even crazier is that despite the growing body of anecdotal evidence and early studies showing the potential benefits of CBD, the medical community often hesitates to fully embrace it because of the lack of large-scale clinical trials. It’s a bit of a catch-22: no big trials without pharma, but no pharma without a profit motive.
Thankfully, more research is being done in the wellness and academic spaces, and hopefully, over time, we’ll see more robust studies that provide clearer guidelines on CBD's uses. The demand for natural alternatives like CBD is definitely pushing this conversation forward!